CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer

BACKGROUND: The investigational use of zolbetuximab (IMAB362), a groundbreaking monoclonal antibody medication targeting claudin 18.2 (CLDN18.2), for treatment of advanced gastrointestinal cancers is currently underway. The unclear clinicopathological characteristics and tumour immune microenvironme...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Canming, Wang, Yukai, Chen, Jinxia, Wang, Yi, Pang, Chuhong, Liang, Chen, Yuan, Li, Ma, Yubo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428652/
https://www.ncbi.nlm.nih.gov/pubmed/37582713
http://dx.doi.org/10.1186/s12876-023-02924-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428652/
https://www.ncbi.nlm.nih.gov/pubmed/37582713
http://dx.doi.org/10.1186/s12876-023-02924-y

Ejemplares similares